NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $4.27 -0.26 (-5.74%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$4.25 -0.02 (-0.37%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IRWD alerts:Sign Up Key Stats Today's Range$4.25▼$4.5450-Day Range$3.56▼$4.5352-Week Range$1.26▼$5.78Volume1.66 million shsAverage Volume1.90 million shsMarket Capitalization$705.57 millionP/E Ratio5.55Dividend YieldN/APrice Target$6.23Consensus RatingModerate Buy Company Overview Ironwood Pharmaceuticals, Inc. is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain. Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S. Food and Drug Administration in 2012 and is marketed in the United States through a collaboration with AbbVie. Linaclotide is also marketed internationally under the brand name CONSTELLA through regional commercial partnerships. Ironwood continues to invest in gastrointestinal drug development, including therapies designed to address chronic and debilitating digestive conditions. The company serves patients and healthcare providers in the United States and selected international markets through its commercial partnerships, while focusing its internal operations on research, development, and commercialization of gastrointestinal medicines.AI Generated. May Contain Errors. Read More Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 397th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialIronwood Pharmaceuticals has a consensus price target of $6.23, representing about 46.0% upside from its current price of $4.27.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to decrease in the coming year, from $1.10 to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is 5.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is 5.55, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.78% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 2.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.59 News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ironwood Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows14 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $578,063.00 in company stock.Percentage Held by Insiders9.30% of the stock of Ironwood Pharmaceuticals is held by insiders.Percentage Held by InstitutionsIronwood Pharmaceuticals has minimal institutional ownership at this time.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRWD Stock News HeadlinesIronwood Pharmaceuticals, Inc. (IRWD)September 23 at 6:12 AM | finance.yahoo.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above Two Hundred Day Moving Average - Here's What HappenedSeptember 16, 2026 | americanbankingnews.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 24 at 1:00 AM | Stansberry Research (Ad)Ironwood: Medicare Is Not The Problem I Thought It WasSeptember 11, 2026 | seekingalpha.comIronwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare ConferenceSeptember 3, 2026 | businesswire.comIronwood Pharmaceuticals: High Dependence On Its Next TrialAugust 26, 2026 | seekingalpha.comIronwood Pharmaceuticals Inc Class A IRWDAugust 13, 2026 | morningstar.comMIronwood Pharmaceuticals’ Earnings Call Highlights LINZESS SurgeAugust 6, 2026 | tipranks.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $3.37 at the beginning of 2026. Since then, IRWD stock has increased by 26.7% and is now trading at $4.27. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by $0.01. The biotechnology company had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 58.38% and a net margin of 33.36%. Read the conference call transcript. When did Ironwood Pharmaceuticals IPO? Ironwood Pharmaceuticals (IRWD) raised $250 million in an initial public offering (IPO) on Wednesday, February 3rd 2010. The company issued 16,666,667 shares at a price of $14.00-$16.00 per share. Who are Ironwood Pharmaceuticals' major shareholders? Top institutional shareholders of Ironwood Pharmaceuticals include Bank of New York Mellon Corp (0.31%), Wellington Management Group LLP (0.28%), Wedge Capital Management L L P NC (0.27%) and Globeflex Capital L P (0.16%). Insiders that own company stock include Alexander J Denner, Thomas A Mccourt, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Andrew Davis, Minardo John, Julie Mchugh, Jon R Duane and Catherine Moukheibir. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IRWD's financial health is in the Green zone, according to TradeSmith. IRWD has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees100Year Founded1998Price Target and Rating Average Price Target for Ironwood Pharmaceuticals$6.23 High Price Target$10.00 Low Price Target$3.70 Potential Upside/Downside+46.0%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.77 Trailing P/E Ratio5.55 Forward P/E Ratio3.88 P/E GrowthN/ANet Income$24.02 million Net Margins33.36% Pretax Margin53.27% Return on Equity-58.38% Return on Assets34.93% Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06 Sales & Book Value Annual Sales$296.15 million Price / Sales2.38 Cash Flow$0.24 per share Price / Cash Flow17.58 Book Value($1.61) per share Price / Book-2.65Miscellaneous Outstanding Shares165,240,000Free Float149,873,000Market Cap$705.57 million OptionableOptionable Beta0.20 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:IRWD) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
